Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.ncbi.nlm.nih.gov › pmc › articlesBiologic Treatments of Psoriasis: An Update for the Clinician

   www.ncbi.nlm.nih.gov › pmc › articles

   16 lut 2021 · It is the only biologic with data and FDA labeling specifically for genital plaque psoriasis. Also, ixekizumab is the only IL-17 agent that is FDA approved for treatment of plaque psoriasis down to the age of 6 years old.

   • Open in a Separate Window

     Head-to-head comparison showed faster onset of action for...

   • Table 1

     Only biologic agent FDA approved for treatment of genital...

   • PMC Free Article

     Tildrakizumab is a high‐affinity, humanized, immunoglobulin...

   • PubMed

     Observations: Plaque psoriasis is the most common variant of...

2. www.ncbi.nlm.nih.gov › pmc › articlesLatest Advances for the Treatment of Chronic Plaque Psoriasis...

   www.ncbi.nlm.nih.gov › pmc › articles

   29 cze 2021 · Deucravacitinib (BMS-986165) is an oral Tyrosine kinase 2 (TYK2) selective inhibitor developed by Bristol-Myers Squibb for the treatment of moderate to severe chronic plaque psoriasis and psoriatic arthritis.

3. www.ncbi.nlm.nih.gov › books › NBK585965Newer Biologics for the Treatment of Plaque Psoriasis

   www.ncbi.nlm.nih.gov › books › NBK585965

   1 wrz 2021 · Newer biologics such as secukinumab, ixekizumab, brodalumab and risankizumab were more favourable compared to older biologics (adalimumab, etanercept, and ustekinumab) in reaching 90% or 100% skin clearance, as measured with the Psoriasis Area Severity Index. The risk of side effects was similar between the newer and older biologics. Go to:

4. jamanetwork.com › journals › jamadermatologyComparison of Biologics and Oral Treatments for Plaque Psoriasis

   jamanetwork.com › journals › jamadermatology

   • Zapisane w pamięci cache

   In the absence of head-to-head randomized clinical trials of treatments for moderate to severe plaque psoriasis, this study provides what we believe to be a comprehensive assessment of the comparative short-term and long-term efficacy among several novel treatments.

5. pubmed.ncbi.nlm.nih.gov › 34239295Latest Advances for the Treatment of Chronic Plaque Psoriasis...

   pubmed.ncbi.nlm.nih.gov › 34239295

   29 cze 2021 · Different classes of biologicals have been already approved, including TNF-α (etanercept, infliximab, adalimumab and certolizumab pegol), IL-12/23 (ustekinumab), IL-17 (secukinumab, ixekizumab, brodalumab) and IL-23 (guselkumab, risankizumab, tildrakizumab) inhibitors.

6. pubmed.ncbi.nlm.nih.gov › 33623366Biologic Treatments of Psoriasis: An Update for the Clinician

   pubmed.ncbi.nlm.nih.gov › 33623366

   16 lut 2021 · The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enhanced.

7. academic.oup.com › bjd › article2020 Guidelines for biologic treatments for psoriasis

   academic.oup.com › bjd › article

   • Zapisane w pamięci cache

   1 paź 2020 · There are now 11 licensed and NICE‐approved biologics for use in psoriasis. This 2020 evidence‐based guideline has been developed by a multi‐stakeholder guideline group with the British Association of Dermatologists, and provides recommendations on how to use these important drugs effectively and safely to maximise patient benefit.